Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Argos raises $35.2 million in series C financing
Argos has received more than half of the total proceeds of the financing, with the balance scheduled to be received by the company in late 2008. Proceeds from
Argos has received more than half of the total proceeds of the financing, with the balance scheduled to be received by the company in late 2008. Proceeds from
The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers. Carsten Reinhardt, chief medical officer of Micromet, said:
The 14-day, randomized, double-blind trial in 798 patients evaluated two concentrations of epinastine (0.10% and 0.15%) at two spray volumes compared to placebo in patients with documented seasonal
This new trial will study the use of IL-7/CYT107 in the treatment of post-transplant patients with T-cell depleted bone marrow or peripheral blood stem cell transplants. The initial
Micrus will be responsible for overseeing the regulatory and clinical process and will be the exclusive worldwide distributor for neurovascular products developed based on this collaborative agreement. Under
Eurand plans to file a marketing authorization application for EUR-1008 (Zentase), the company’s pancreatic enzyme product candidate, through a centralized procedure, the approval of which would allow market
Under the terms of the merger agreement, OccuLogix will be acquiring the minority ownership interest in OcuSense by way of a merger of OcuSense and a newly incorporated,
The Conquer study (OB-303) enrolled patients with a body mass index (BMI) ranging from 27 to 45 and at least two additional co-morbidities. The co-primary endpoints for this
The Phase III study design agreed with the FDA follows directly from the study design successfully employed in Phase II. The Phase III study will also enroll previously
Bexion has demonstrated that specific versions of these nanovesicles can be used to selectively target a broad range of tumors (both solid and hematologic). Specific formulations have also